Published in Lab Business Week, August 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at BioSante Pharmaceuticals, Inc.
Report 1: BioSante Pharmaceuticals, Inc. (AMEX: BPA) announced the launch of Elestrin (estradiol gel 0.06%) by the Kenwood Therapeutics Division of Bradley Pharmaceuticals, Inc. (NYSE: BDY). Elestrin is an effective, ultra-low dose transdermal estrogen therapy that was approved by the U.S. Food and Drug Administration (FDA) in December 2006 for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week